Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up

This study strongly suggested that the RLAI treatment, even with only partial switching, provides relief from refractory symptoms, particularly for patients with a history of DSP. Clinical trial registration: http://www.umin.ac.jp/:UMIN000008487

http://jop.sagepub.com/cgi/content/abstract/30/8/795?rss=1

Source: Journal of Psychopharmacology - July 12, 2016 Category: Psychiatry Authors: Kimura, H., Kanahara, N., Sasaki, T., Komatsu, N., Ishige, M., Muneoka, K., Ino, H., Yoshimura, K., Yamanaka, H., Suzuki, T., Komatsu, H., Watanabe, H., Shimizu, E., Iyo, M. Tags: Original Papers Source Type: research